TY - JOUR ID - 3814 TI - Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease JO - Journal of Patient Safety & Quality Improvement JA - PSJ LA - en SN - 2345-4482 AU - Rahimi, Hossein AU - Jafarian, Amir Hosein AU - Samadi, Alireza AU - Meamar, Bahram AD - Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran AD - Cancer Molecular Pathology Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Patient Safety Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Y1 - 2015 PY - 2015 VL - 3 IS - 1 SP - 198 EP - 200 KW - Diffuse large B-cell lymphoma KW - MUM1 KW - BCL6 DO - 10.22038/psj.2015.3814 N2 - Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) which includes about (25%) of the cases. Patients with DLBCL have a rapidly growing mass that is located in the neck or abdominal region. Multiple Myeloma Oncogene (MUM1) has an important role in lymphoid cell differentiation. MUM1/IRF4 is as oncogene related to myeloma and translocation (p25; q32), t (6; 14) and leads to a change in the heavy chain of Immunoglobulin (IGH). BCL6 exists in approximately (100%) of follicular cell cancer cases, (100%) of Burkitt lymphoma, (80%) of large B-cell lymphoma, and in more than (80%) of nodular lymphocytic Hodgkin lymphoma cases. BCL6 is related to cancers with a high proliferation cell index. In some studies BCL6 is expressed as a prognostic factor in LBCL patients UR - https://psj.mums.ac.ir/article_3814.html L1 - https://psj.mums.ac.ir/article_3814_6825530c5a8c66f49e20f7286b63d927.pdf ER -